GFRA3

Across TCGA pan-cancer cohorts, GFRA3 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of GFRA3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where GFRA3 RNA is repressed in tumor relative to normal tissue. In most cancer types GFRA3 is over-expressed in tumor, although a few such as KIRC and BLCA show the opposite, repressed pattern.

KIRC, BLCA, and COAD are the cancer types where GFRA3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GFRA3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	III,IV	−0.478	<.001	12	view →
BLCA	All	IV	−2.219	<.001	11	view →
COAD	Male	All	−1.966	<.001	11	view →
KICH	All	All	−0.600	<.001	10	view →
THCA	All	III,IV	−0.588	<.001	10	view →
KIRP	Male	All	−0.717	<.001	9	view →
STAD	Male	All	−1.825	<.001	8	view →
UCEC	All	All	+2.286	<.001	6	view →
BRCA	All	III,IV	−0.611	<.001	6	view →
READ	All	All	−2.590	<.001	3	view →
ESCA	Female	All	−1.830	.012	2	view →
PRAD	All	All	−0.788	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

GFRA3–KIRC

Open the KIRC breakdown →